NCT04916899View on ClinicalTrials.gov

Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program

CompletedOBSERVATIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Tuberculosis
Interventions
DRUG

Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol

Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral

Trial Locations (1)

11000

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY

NCT04916899 - Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program | Biotech Hunter | Biotech Hunter